GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 181-192 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.

Ramzy D; Isshak R; Patel D; Elmasry M; Shri N; Romero J; Paromita P; Nazmee T; Shamoon F

Jan 1, 2026Cureus

2026PubMedDirectly related

Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.

Ming Q; Li Z; Cui J

Jan 1, 2026Frontiers in nutrition

2026PubMedDirectly related

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.

Hölscher C

Jan 1, 2026Frontiers in neuroscience

2026PubMedDirectly related

Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis.

Xie Y; Zhang X; Chen B

Jan 1, 2026Frontiers in medicine

2026PubMedDirectly related

Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens.

Bujdei-Tebeică I; Pantea-Stoian AM; Mihai DA; Ștefan SD; Serafinceanu C

Jan 1, 2026

2026PubMedDirectly related

Real-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study.

Mahmoud NM; Hussein A; Mussa BM; Abusnana S

Jan 1, 2026Clinical medicine insights. Endocrinology and diabetes

2026CrossrefDirectly related0 citations

The Dual-Agonist Advantage: Comparing Tirzepatide (GIP/GLP-1) Efficacy Against Single GLP-1 RAs (Semaglutide) in T2DM

2026CrossrefDirectly related0 citations

NOVA ERA DO TRATAMENTO DA OBESIDADE: EFEITOS DOS AGONISTAS DO GLP-1, DUPLOS (GIP) E TRIPLOS (GLUCAGON) NO DIABETES MELLITUS, OBESIDADE E DEMAIS DESFECHOS SISTÊMICOS – REVISÃO INTEGRATIVA

2026PubMedDirectly related

Real-World Effectiveness and Safety of GLP-1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery.

Yuce T; Radwan RM; Lee YA; Holler E; Dai H; He X; Huang Y; Guo Y; Bian J; Guo J

Jan 1, 2026

2026PubMedDirectly related

Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.

Yu H; Wang J; Yin M; Ji L; Guo S; Liu T; Wang R

Jan 1, 2026

2026PubMedDirectly related

GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far.

Raja NP; Kandagari N

Jan 1, 2026Current oncology reports

2026PubMedDirectly related

Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.

Dhali A; Biswas J; Khan F; Dahiya DS; Mandal S

Jan 1, 2026